REVELATION BIOSCIENCES, INC. (REVB) Form 10-Q — Nov 5, 2026
Revelation Biosciences reported a net loss of $9.6 million for the nine months ended September 30, 2026, up from $6.4 million a year ago, with cash of $9.1 million and an accumulated deficit of $59.1 million. Management stated that current cash will not sustain operations within one year, raising substantial doubt about the company's ability to continue as a going concern. A newly effective Nasdaq rule requires automatic delisting if the market value of listed securities stays below $5 million for 30 consecutive business days, and the company disclosed its market value is already below that threshold with no cure period.
Key figures
- Total Assets
- 10022097
- Cash Position
- 9121630
- Shares Outstanding
- 683442
- Q3 2026 net loss
- $3,315,513
- Net loss 9mo 2025
- $6.4 million
- Accumulated deficit
- $59.1 million
- Ga expense 9mo 2026
- $5,330,134
- Rd expense 9mo 2026
- $4,808,183
- Stockholders equity
- $7.2 million
- Warrants outstanding
- 1273796
- Cumulative gross raised
- $75.9 million net proceeds since inception
- Net cash used in operating 9mo
- $8.1 million
- Total potentially dilutive securities
- 1316468
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.